Nebhan CA, Cortellini A, Ma W, et al. - Treatment with immune checkpoint inhibitors (ICIs) can be beneficial for geriatric patients with cancer, but this population has a lower threshold for and higher rate of immune-related adverse event (irAE)-related ICI discontinuation with increasing age.

• This is a cohort study of 928 patients 80 years or older with different tumors treated with single-agent ICIs between 2010 to 2019 from 18 academic centers in the US and Europe.

• Of participants, 41.3% experienced ≥1 irAE(s).

• Promising antitumor outcomes with single-agent ICIs were achieved in non–small cell lung cancer (NSCLC), melanoma, and genitourinary (GU) tumors; although no significant difference existed in rate of irAEs, a higher irAE-related ICI discontinuation was noted in patients aged 90 years or older, even for lower-grade irAEs.

• For NSCLC, melanoma, and GU, the objective response rates were 32.2%, 39.3%, and 26.2%, respectively; median PFS and OS, respectively, were 6.7 and 10.9 months (NSCLC), 11.1 and 30.0 months (melanoma), and 6.0 and 15.0 months (GU).

• Overall, ICIs could be effective and generally have good tolerability in older patients with cancer, though ICI discontinuation due to irAEs was more frequent with increasing age.